评估患者对新型过敏性鼻炎治疗工具（患者获益指数）的期望和获益：benefica 研究。
Evaluation of patients' expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index - the benefica study.
机构信息
Department of Pulmonology - Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier cedex 5, France and Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013 Paris, France.
Service de Pneumologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France ; Université Paris Diderot - Paris 7, Paris, France ; INSERM Unité 700, Faculté de Médecine Bichat, Paris, France.
出版信息
Allergy Asthma Clin Immunol. 2015 Feb 26;11(1):8. doi: 10.1186/s13223-015-0073-1. eCollection 2015.
BACKGROUND
Symptoms of allergic rhinitis (AR) have a detrimental effect on quality of life. The AR-Patient Benefit Index (AR-PBI), a specific self-assessment tool has been developed to assess treatment-related benefit in two separate sections: the Patient Needs Questionnaire (PNQ) which explores the patient's expectations before treatment and the Patient Benefit Questionnaire (PBQ) which evaluates treatment benefit. For the PNQ, three dimensions summarize patients' expectations: symptoms, social life and emotional state, thus covering a larger field than symptomatic relief. The aim of the study was to validate the French language version of the AR-PBI and to assess the treatment-related expectations and benefits provided in patients with allergic rhinitis treated with H1-antihistamines in a real-life study.
METHODS
BENEFICA was a prospective, observational study involving patients with allergic rhinitis who were starting treatment with H1-antihistamines. The Patient Needs Questionnaire (PNQ) was administered before treatment (D0) and the Patient Benefit Questionnaire (PBQ) was collected after a 14-day course of H1-antihistamines (D15). Discomfort (visual analog scale), and quality of life (miniRQLQ) were measured on D0 and D15.
RESULTS
Three thousands and eighty-nine patients were enrolled in the study: mean age 39 ± 14 years, women 52%, 81% of patients with moderate to severe persistent rhinitis (Allergic Rhinitis and its Impact on Asthma, ARIA); 19% had (a) concomitant condition(s), 18% were asthmatic, and 12% had atopic dermatitis. Discomfort and quality of life improved between D0 and D15. AR-PBI was 2.7 ± 0.8, superior to 1 (threshold for clinically relevant benefit) for 97% of patients and greater in patients willing to continue the treatment. PBI was moderately correlated to change in miniRQLQ (r = -0.45, p < 0.0001) and change in discomfort (r = -0.38, p < 0.0001), suggesting a richer conceptual content than symptoms relief.
CONCLUSIONS
The French version of the Allergic Rhinitis-Patient Benefit Index (AR-PBI) has been validated. It complements the discomfort and quality of life tools and assesses the needs and benefits in patients suffering from allergic rhinitis. This new tool may help physicians to better understand patients' expectations and to discuss treatment issues with their patients.
背景
过敏性鼻炎（AR）的症状会对生活质量产生不利影响。AR-患者获益指数（AR-PBI）是一种专门的自我评估工具，已开发用于在两个单独的部分评估治疗相关获益：患者需求问卷（PNQ），用于评估患者在治疗前的期望；患者获益问卷（PBQ），用于评估治疗获益。PNQ 用三个维度总结了患者的期望：症状、社会生活和情绪状态，因此涵盖了比症状缓解更广泛的领域。本研究的目的是验证法语版 AR-PBI，并在现实生活中评估接受 H1 抗组胺治疗的过敏性鼻炎患者的治疗相关期望和获益。
方法
BENEFICA 是一项前瞻性、观察性研究，纳入了开始接受 H1 抗组胺治疗的过敏性鼻炎患者。在治疗前（D0）进行患者需求问卷（PNQ），在接受 H1 抗组胺治疗 14 天后（D15）进行患者获益问卷（PBQ）。在 D0 和 D15 时测量不适（视觉模拟量表）和生活质量（miniRQLQ）。
结果
共纳入 3089 例患者：平均年龄 39±14 岁，女性占 52%，81%为中重度持续性鼻炎（过敏性鼻炎及其对哮喘的影响，ARIA）；19%有（一种或多种）并存疾病，18%为哮喘患者，12%为特应性皮炎患者。D0 至 D15 时不适和生活质量均改善。AR-PBI 为 2.7±0.8，97%的患者优于 1（具有临床相关获益的阈值），愿意继续治疗的患者获益更大。PBI 与 miniRQLQ 的变化（r=-0.45，p<0.0001）和不适的变化（r=-0.38，p<0.0001）中度相关，表明其概念内容比症状缓解更丰富。
结论
验证了法语版过敏性鼻炎-患者获益指数（AR-PBI）。它补充了不适和生活质量工具，并评估了患有过敏性鼻炎患者的需求和获益。这种新工具可能有助于医生更好地了解患者的期望，并与患者讨论治疗问题。
Zotero 插件